Tultepec

Researchers are evaluating whether eptinezumab can reduce the number of migraine days compared to a placebo in adolescents aged 12 to 17 with chronic migraine. This Phase 3, randomized, double-blind study aims to assess the preventive treatment effects of intravenous eptinezumab in this young population who experience frequent migraines. Participants will be randomly assigned to receive a single intravenous infusion of either eptinezumab 300 mg, eptinezumab 100 mg both doses adjusted by body weight, or a placebo. The study includes a 4-week screening period, followed by a 12-week double-blind treatment phase and an 8-week safety follow-up period. The doses are designed to target adult exposure levels based on weight. During the study, participants will complete a headache electronic diary to track migraine and headache days. Researchers will monitor changes in monthly migraine days over 12 weeks as the primary outcome. Additional assessments include migraine reduction percentages, medication usage, headache severity, disability scores, and blood tests for drug levels and antibodies. Safety and tolerability will be evaluated through the follow-up period, totaling about 24 weeks of participation.

Researchers are evaluating ziltivekimab, a new medicine not yet approved anywhere, to see if it can help people who were hospitalized due to a heart attack. The study aims to find out if ziltivekimab can reduce the development of heart disease and prevent future heart attacks or strokes. This is a Phase 3 clinical trial comparing ziltivekimab to a placebo in patients with acute myocardial infarction. Participants will receive an initial loading dose of ziltivekimab or matching placebo by injection under the skin as soon as possible after an invasive heart procedure, within 36 hours for STEMI or 48 hours for NSTEMI patients. After the loading dose, they will get monthly injections of the same study medicine for up to two years, in addition to their standard care. During the study, participants will be monitored for major cardiovascular events such as heart attack, stroke, and cardiovascular death. Researchers will also track other heart-related outcomes and safety measures over a period of up to 25 months. The study involves regular visits for injections, assessments, and laboratory tests to evaluate the medicines effects and patient health throughout the trial.